Oscient Pharmaceuticals Corp Watch

from S-4/A 43 pages Dealer Manager Agreement October , 2008

from S-1/A 42 pages Placement Agent Agreement April , 2007

from S-4/A 42 pages Placement Agent Agreement April , 2007

from S-1/A 45 pages Dealer Manager Agreement March 29, 2007

from S-4/A 45 pages Dealer Manager Agreement March 29, 2007

from 8-K 4 pages Oscient Pharmaceuticals Corporation 2001 Incentive Plan Restricted Stock Award Agreement

from 8-K 4 pages Oscient Pharmaceuticals Corporation 2001 Incentive Plan Nonstatutory Stock Option Grant Agreement

from 8-K 4 pages Oscient Pharmaceuticals Corporation 2001 Incentive Plan Incentive Stock Option Grant Agreement

from SC 13G/A 1 page Exhibit 1 Joint Filing Agreement in Accordance With Rule 13d-1(k) (1) (III) Under the Securities Exchange Act of 1934, as Amended, the Persons Named Below Agree to the Joint Filing on Behalf of Each of Them of a Statement on Schedule 13g/a Filed on June 10, 2003 (Including Amendments Thereto) With Respect to the Common Stock of Genome Therapeutics Corp. This Joint Filing Agreement Shall Be Filed as an Exhibit to Such Statement. Dated: June 10, 2003 Smithfield Fiduciary LLC By: /S/ Howard Feitelberg Howard Feitelberg, Director Highbridge International LLC By: /S/ Howard Feitelberg Howard Feitelberg, Director Highbridge Capital Corporation By: /S/ Howard Feitelberg Howard Feitelberg, Controller Highbridge Capital Management, LLC By: /S/ Ronald S. Resnick Ronald S. Resnick, Managing Director

from 8-K 1 page Underwriting agreement

from SC 13G/A 1 page <page> Exhibit 1 Agreement Regarding Joint Filing the Undersigned, Biotechnology Value Fund, L.P., a Delaware Limited Partnership, Biotechnology Value Fund II, L.P., a Delaware Limited Partnership, Bvf Investments, L.L.C., a Delaware Limited Liability Company, Bvf Partners L.P., a Delaware Limited Partnership, and Bvf Inc., a Delaware Corporation, Hereby Agree and Acknowledge That the Information Required by the Amendment to Schedule 13g, to Which This Agreement Is Attached as an Exhibit, Is Filed on Behalf of Each of Them. the Undersigned Further Agree That Any Further Amendments or Supplements Thereto Shall Also Be Filed on Behalf of Each of Them. Dated: June 15, 2001 Biotechnology Value Fund, L.P. By: Bvf Partners L.P., Its General Partner By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Biotechnology Value Fund II, L.P. By: Bvf Partners L.P., Its General Partner By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Bvf Investmetns L.L.C. By: Bvf Partners L.P., Its Manager By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Bvf Partners L.P. By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Bvf Inc. By: /S/ Mark N. Lampert Mark N. Lampert President

from SC 13G/A 1 page <page> Exhibit 1 Agreement Regarding Joint Filing the Undersigned, Biotechnology Value Fund, L.P., a Delaware Limited Partnership, Biotechnology Value Fund II, L.P., a Delaware Limited Partnership, Bvf Investments L.L.C., a Delaware Limited Liability Company, Bvf Partners L.P., a Delaware Limited Partnership, and Bvf Inc., a Delaware Corporation, Hereby Agree and Acknowledge That the Information Required by the Amendment to Schedule 13g, to Which This Agreement Is Attached as an Exhibit, Is Filed on Behalf of Each of Them. the Undersigned Further Agree That Any Further Amendments or Supplements Thereto Shall Also Be Filed on Behalf of Each of Them. Dated: January 10, 2001 Biotechnology Value Fund, L.P. By: Bvf Partners L.P., Its General Partner By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Biotechnology Value Fund II, L.P. By: Bvf Partners L.P., Its General Partner By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Bvf Investments, L.L.C. By: Bvf Partners L.P., Its Manager By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Bvf Partners L.P. By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Bvf Inc. By: /S/ Mark N. Lampert Mark N. Lampert President

from SC 13G 1 page <page> Exhibit 1 Exhibit 1 Agreement Regarding Joint Filing the Undersigned, Biotechnology Value Fund, L.P., a Delaware Limited Partnership, Biotechnology Value Fund II, L.P., a Delaware Limited Partnership, Bvf Partners L.P., a Delaware Limited Partnership, and Bvf Inc., a Delaware Corporation, Hereby Agree and Acknowledge That the Information Required by Schedule 13g, to Which This Agreement Is Attached as an Exhibit, Is Filed on Behalf of Each of Them. the Undersigned Further Agree That Any Amendments or Supplements Thereto Shall Also Be Filed on Behalf of Each of Them. Dated: December 11, 2000 Biotechnology Value Fund, L.P. By: Bvf Partners L.P., Its General Partner By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Biotechnology Value Fund II, L.P. By: Bvf Partners L.P., Its General Partner By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Bvf Partners L.P. By: Bvf Inc., Its General Partner By: /S/ Mark N. Lampert Mark N. Lampert President Bvf Inc. By: /S/ Mark N. Lampert Mark N. Lampert President

from POS EX ~5 pages Underwriting agreement

from S-3/A ~20 pages Underwriting agreement

from S-3/A ~20 pages Underwriting Agreement

from S-3 ~20 pages Underwriting Agreement